Menu
Back to Journals » Cancer Management and Research » Volume 12
Review
Ramucirumab, A Second-Line Option For Patients With Hepatocellular Carcinoma: A Review Of The Evidence
| Total article views | HTML views | PDF downloads | Totals | ||
|---|---|---|---|---|---|
| 8,556 | Dovepress* | 5,981+ | 1,773 | 7,754 | |
| PubMed Central* | 2,575 | 435 | 3,010 | ||
| Totals | 8,556 | 2,208 | 10,764 | ||
| *Since 20 May 2020 | |||||
View citations on PubMed Central and Google Scholar